Improved treatment results have been obtained when therapeutic drugs are concentrated in the targeted tissues, such as cancer cells, due to the targeting capability provided by ligands such as folic acid, which can bind with the folate receptor, or HER2 antibodies, which target HER2-positive cells specifically [276]. The gene discussed is ERBB2; the disease is cancer.